Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track BIAF with free AI briefings, catalyst countdowns, and dilution alerts.

BIAF · bioAffinity Technologies, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

On the Downside Radar. Closed at $2.00, 58% below $4.73, its close on the day of its Oct 9 private placement. Of biotech stocks this far below their close on the day of a recent offering, 76% were lower 60 trading days later (median -29%). How we know
$2.6M Cash on Hand
2.2mo Cash Runway
4.2% Short Interest
Follow BIAF by email Get an email when BIAF reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about BIAF, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

💰 Cash Runway & Dilution Risk

BIAF holds $2.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $3.5M/quarter from operations, an estimated runway of 2.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 60 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BIAF files for a raise →

👥 Who Owns BIAF

Insiders 100% Institutions 0% Public and other holders 0%
HolderTypeShares% of sharesAs of
Gary D Rubin
Director, 10% owner
Insider 1,730,741 95.10% 2024-07-01
Steven Girgenti
Executive Chairman, Director
Insider 1,089,017 59.84% 2025-01-10
Roby Joyce
Director
Insider 649,745 35.70% 2024-07-01
Maria Zannes
President & CEO, Director
Insider 280,359 15.40% 2025-01-10
Robert A. Anderson
Director
Insider 163,936 9.01% 2024-07-01
James Michael Edwards
VP and CFO
Insider 120,128 6.60% 2025-01-10
Peter S Knight
Director
Insider 117,455 6.45% 2024-07-01
Stuart Diamond
Director
Insider 99,088 5.44% 2024-07-01
HRT Financial LP Institution (13F) 91,431 5.02% 2026-09-30
Michael Philip Dougherty
Chief Financial Officer
Insider 84,203 4.63% 2024-01-31
Timothy P Zannes
Secretary, EVP, Gen. Counsel
Insider 54,765 3.01% 2025-01-10
Jamie Platt
Director
Insider 54,748 3.01% 2024-07-01

Share count 1,820,006 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full BIAF picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BIAF and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.